Abstract
The laccase induced gelation of maize bran arabinoxylans at 2.5% (w/v) in the presence of insulin or β-lactoglobulin at 0.1% (w/v) was investigated. Insulin and β-lacto-globulin did not modify either the gel elasticity (9 Pa) or the cross-links content (0.03 and 0.015 μg di- and triferulic acids/mg arabinoxylan, respectively). The protein release capability of the gel was also investigated. The rate of protein release from gels was dependent on the protein molecular weight. The apparent diffusion coefficient was 0.99 × 10-7 and 0.79 × 10-7 cm2/s for insulin (5 kDa) and β-lactoglobulin (18 kDa), respectively. The results suggest that maize bran arabinoxylan gels can be potential candidates for the controlled release of proteins.
Highlights
Polysacharide gels have been widely investigated as matrices for protein delivery [1]
The results suggest that maize bran arabinoxylan gels can be potential candidates for the controlled release of proteins
From 1.75 to 100 mg of protein per mL of arabinoxylan gel have been entrapped in previous studies [1,6], where the addition of protein to arabinoxylan in protein/arabinoxylan mass ratio from 1 to 10 led to a 73% loss in G’, in spite of a similar content in di-ferulic acid (FA) and triFA covalent cross-links
Summary
Polysacharide gels have been widely investigated as matrices for protein delivery [1]. The development of oral delivery systems that improve absorption of therapeutic proteins is one of the greatest challenges in the pharmaceutical field. Due to their attractive biodegradable, biocompatible, Molecules 2009, 14 non-toxic and hydrophilic properties and their mild cross-linking conditions, natural polysaccharides such as chitosan, starch, alginate, dextran and arabinoxylan, among others, are receiving incresing attention as colloidal carriers. In this work maize bran arabinoxylan (MBAX) gels were formed around insulin or β-lactoglobulin as model proteins and the effect of protein molecular weight on the gel elasticity, cross-linking content and in vitro protein release capability was investigated
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
